foxo4-dri clinical trial nct FOXO - FOXO4-DRIprotocol study Unraveling the Potential of FOXO4-DRI in Clinical Trials: Targeting Senescence for Therapeutic Advancement

FOXO4-DRIDosage chart PDF The burgeoning field of anti-aging research is increasingly focused on cellular senescence, a state where cells cease to divide and accumulate with age, contributing to various age-related diseases. A significant area of investigation within this domain is the development of senolytic therapies, which aim to selectively eliminate these senescent cells. Central to this pursuit is the synthetic senolytic peptide FOXO4-DRI, a molecule that has garnered considerable attention for its ability to disrupt the binding between FOXO4 and p53, thereby triggering apoptosis in senescent cells. This article delves into the current understanding of FOXO4-DRI clinical trial research, exploring its mechanisms, potential applications, and the ongoing scientific inquiry surrounding this promising therapeutic agent.Cellular senescence in brain aging and neurodegeneration

Understanding the Mechanism: The FOXO4-p53 Axis

At the heart of FOXO4-DRI's action lies its targeted disruption of the interaction between FOXO4, a transcription factor, and p53, a critical tumor suppressor protein. This interaction is pivotal in maintaining the viability of senescent cells.2025年10月21日—This article examines the speculated properties ofFOXO4-DRIbased on actual molecular findings, outlines its potentialresearchimplications in ... FOXO4-D-retro-inverso (FOXO4-DRI), a peptide analog, is designed to interfere with this binding. By preventing FOXO4 from interacting with p53, FOXO4-DRI effectively prompts senescent cells towards programmed cell death, or apoptosis. This targeted approach is crucial, as it aims to spare healthy, non-senescent cells from harm.FOXO4-DRI causes nuclear exclusion of active p53 and ... Early research has indicated that FOXO4-DRI causes nuclear exclusion of active p53 and subsequent apoptosis in senescent TM3 Leydig cells. The peptide's efficacy in inducing apoptosis and reducing senescent cell numbers has been compared to other agents, with studies suggesting FOXO4-DRI was as effective as GCV in certain contexts.

FOXO4-DRI in Preclinical Studies: A Glimpse of its Potential

Preclinical studies employing animal models have provided compelling evidence for FOXO4-DRI's therapeutic potential across a range of conditions associated with aging. For instance, in aged mice, FOXO4-DRI alleviates age-related testosterone secretion insufficiencyFOXO4-DRI causes nuclear exclusion of active p53and induces apoptosis in senescent TM3 Leydig cells. (A) Immunofluorescent staining showing increased .... These studies observed that FOXO4-DRI improved the testicular microenvironment and mitigated the decline in testosterone production. Furthermore, FOXO4-DRI has been shown to restore fitness, fur density, and renal function in both rapidly aging mice and naturally aging mice. Its ability to selectively eliminates senescent cells extends to various cell types, including chondrocytes. Notably, FOXO4-DRI treatment could remove the senescent cells in the expanded chondrocytes, and it has also demonstrated efficacy in removing senescent cells in PDL9 chondrocytes, suggesting potential applications in cartilage-related conditions.作者：B Bourgeois·2025·被引用次数：11—We recently identified theFOXO4– p53 axis as pivotal in maintaining the viability of senescent cells, and that senescent cells can be targeted ... Beyond these, research has also indicated that FOXO4-DRI can neutralize doxorubicin-induced chemotoxicity in mice, suggesting a potential role in supporting patients undergoing certain cancer therapies.

The Journey Towards Human Application: FOXO4-DRI Clinical Trials

While preclinical data is encouraging, the progression to human clinical trials is a critical step in validating the safety and efficacy of any potential therapeutic. The search for FOXO4-DRI clinical trial information, including FOXO4---DRIprotocol, FOXO4---DRIhuman trials, and FOXO4---DRIdosage, is indicative of the growing interest in translating these findings to human health. Although specific large-scale human trials may still be in nascent stages or proprietary, the scientific community is actively exploring the therapeutic avenues that FOXO4-DRI might offerFOXO4-DRI is a synthetic senolytic peptide thatselectively eliminates senescent cells(cell death/apoptosis) by disrupting the FOXO4/p53 interaction..

The potential benefits of FOXO4-DRI are multifaceted作者：Z Hu·2025—Thisstudyaims to analyze the vascular function and aging status of the aorta in naturally aged mice and progeroid model mice followingFOXO4- .... Beyond its role as a senolytic, it is being investigated for its broader anti-aging properties and as a geroprotector.DNA Damage Induced Cell Fates during Aging The concept of reducing "biological age" through interventions that improve cellular function is a key driver in this researchIt is studied for its senolytic properties — selectively targeting senescent cells — with the aim of supporting tissue regeneration, organ health, and longevity .... Anecdotal evidence and early case studies, such as a 2023 report detailing a 32% reduction in senescent cell markers in a 62-year-old patient after 12 weeks of FOXO4-DRI, hint at its real-world applicabilityFOXO4-DRI alleviates age-related testosterone secretion .... However, rigorous, controlled clinical trials are essential to establish definitive FOXO4-DRIbenefits and understand potential FOXO4-DRIside effects.Translating the Biology of Aging into New Therapeutics for ...

Future Directions and Considerations

The research into FOXO4-DRI is dynamic and evolving作者：M Riessland·2024·被引用次数：37—To target this interaction, a senolytic peptide named FOXO4-d-Retro-Inverso (FOXO4-DRI) was developed.FOXO4-DRI disrupts the binding between FOXO4 and p53.... The study of the FOXO4 transcription factor and its role in cellular processes continues to expandIn thisstudy, we observed thatFOXO4-DRI, a specific FOXO4- p53 binding blocker, induced apoptosis in senescent Leydig cells, reduced the secretion of .... As the understanding of senescence and its contribution to disease deepens, so too will the exploration of senolytic agents like FOXO4-DRI. While FOXO4-DRI is the most effective senolytic based on some current assessments, ongoing research aims to optimize its delivery, dosage, and therapeutic windowSenolytic Peptide Foxo4-Dri Selectively Removes Senescent .... Investigating the molecular modeling of the FOXO4-TP53 interaction further refines our understanding of how FOXO4-D-retro-inverso (FOXO4-DRI) functions at a molecular level.

In conclusion, the drug FOXO4 and its derivative, FOXO4-DRI, represent a significant advancement in the quest to combat age-related decline and diseases driven by cellular senescence. The peptide's precise mechanism of action, targeting the FOXO4 and p53 interaction to eliminate senescent cells, positions it as a promising candidate for future therapeutic development作者：M Riessland·2024·被引用次数：37—To target this interaction, a senolytic peptide named FOXO4-d-Retro-Inverso (FOXO4-DRI) was developed.FOXO4-DRI disrupts the binding between FOXO4 and p53.... As clinical trials progress and more data becomes available, the full impact of FOXO4-DRI on human health and longevity will become clearer. The scientific community remains keenly interested in the continued research of this potent senolytic agent.